News for Healthier Living

AACR: Zedoresertib and Lunresertib Combination Shows Promising Antitumor Activity

* Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors * Zedoresertib, which targets WEE1, and lunresertib, a PKMYT1 inhibitor, are both investigational therapies that create synthetic lethality by blocking cell cycle proteins * Combination achieved notable responses in ovarian cancer at the preliminary recommended Phase II dose, with a 50% overall response rate across all patients and a 60% rate in patients with CCNE1 amplification * This combination has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations

April 20, 2026


May 1 2026

April 30 2026

April 29 2026

April 28 2026

April 27 2026

April 26 2026

April 25 2026

April 24 2026

April 23 2026

April 22 2026

April 21 2026

April 20 2026

April 19 2026

April 18 2026